Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib versus placebo added to radiotherapy and androgen deprivation therapy for BRCA-mutated high-risk localized or locally advanced prostate cancer
NL-OMON59997Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Saruparib + standard RT + ADT with Placebo + standard RT + ADT (2 arms). Primary endpoint: Metastasis-free survival. Started Dec 2025; status: recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59997.